Ibuprofen
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Ibuprofen: Acromesomelic dysplasia, Hunter-Thompson type
One-Sentence Summary
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) originally used for rheumatoid arthritis, osteoarthritis, headache, juvenile idiopathic arthritis and patent ductus arteriosus. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction is based on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 0.9974 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Ibuprofen is generally known as a non-selective cyclooxygenase (COX) inhibitor with anti-inflammatory and analgesic effects, and it is established in arthritis and musculoskeletal pain.
Acromesomelic dysplasia, Hunter-Thompson type, is a rare skeletal dysplasia caused by loss-of-function variants in the CDMP1/GDF5 gene, which disrupt cartilage and bone development. COX inhibition has no plausible way to correct this developmental defect. The prediction most likely reflects the model’s network proximity to musculoskeletal and arthropathy indications rather than a biological rationale. At best, ibuprofen might relieve joint pain symptomatically, which is not a disease-modifying effect.
Other top-ranked predictions show the same pattern (all L5, all Hold): brachyolmia-amelogenesis imperfecta syndrome, myosclerosis, brachyolmia, brachydactyly-syndactyly syndrome, pseudoachondroplasia, and colobomatous microphthalmia-rhizomelic dysplasia syndrome. Of these, pseudoachondroplasia (secondary joint pain) and myosclerosis (musculoskeletal pain) have only a speculative symptomatic rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 108439 | Ibufen Tablet | Strip of 10 tablets | Not stated |
| 112546 | Ibugrap 400mg Tablet | Strip of 10 tablets | Not stated |
| 160600 | Nilflam Suspension | Bottle of 60 ml suspension | Not stated |
| 108868 | Ibuset Syrup | Bottle of 60 ml syrup | Not stated |
| 41347 | Corflam Gel | Tube of 15 gm gel (topical) | Not stated |
All 20 registrations are valid single-ingredient licences. Dosage forms include oral tablets, suspensions, syrups and a topical gel.
Safety Considerations
Contraindication-related conditions (from the knowledge graph, not label text): Hypertension, liver failure and liver disease, kidney disease, peptic ulcer disease, inflammatory bowel disease, thrombocytopenia, blood coagulation disease, stroke and cerebrovascular disorders, myocardial infarction, diabetes mellitus and diabetic ketoacidosis, epilepsy, COPD, systemic lupus erythematosus, hypothyroidism, gallbladder disease, potassium deficiency, benign prostatic hyperplasia, hypotensive disorder, and substance abuse/dependence.
Drug Interactions: 687 interactions were recorded. Main examples:
- Major: Acetylsalicylic acid
- Moderate: Corticosteroids (betamethasone, budesonide, dexamethasone, hydrocortisone), sulfonylureas (acetohexamide, chlorpropamide, glimepiride, glipizide, glyburide), exenatide, aprepitant, balsalazide, fenfluramine and dexfenfluramine, kanamycin, levofloxacin
- Minor: Famotidine, ranitidine, cimetidine
Please refer to the package insert for label-based warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score (0.9974), with no clinical trials or publications. There is no plausible mechanism linking COX inhibition to correction of a GDF5-related developmental skeletal defect. Ibuprofen’s safety profile is also considerable for a chronic use in a rare paediatric-onset condition.
To proceed, the following is needed:
- Mechanism of action data for ibuprofen, to allow mechanistic-link analysis
- Package insert warnings and contraindications from the India licences, which are required before safety screening
- Any preclinical or clinical evidence for ibuprofen in GDF5/CDMP1-related skeletal dysplasia
- Route and dosage-form compatibility assessment for the proposed use
- If the aim is symptomatic pain relief, a focused review of ibuprofen in secondary joint pain in skeletal dysplasias (such as pseudoachondroplasia) may be more productive than this top-ranked candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.